Composite chitosan and calcium sulfate scaffold for dual delivery of vancomycin and recombinant human bone morphogenetic protein-2

Journal of Materials Science: Materials in Medicine

Volumn 25, Issue 6, 2014, Pages 1449-1459

  Doty, Heather A ^a   Leedy, Megan R ^a   Courtney, Harry S ^b   Haggard, Warren O ^a   Bumgardner, Joel D ^a  

^a 330 Engineering Technology Building ^*  (United States)

^b UNIVERSITY OF TENNESSEE HEALTH SCIENCE CENTER   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

CALCIUM COMPOUNDS; CHITOSAN; DRIERS (MATERIALS); MICROSPHERES; MULTI AGENT SYSTEMS; RECOMBINANT PROTEINS; SCAFFOLDS (BIOLOGY); SULFUR COMPOUNDS; TARGETED DRUG DELIVERY; TISSUE REGENERATION;

BONE REGENERATION; CHITOSAN MICROSPHERES; COMPOSITE BONES; DELIVERY SYSTEMS; DRUG RELEASE KINETICS; FUNCTIONAL ACTIVITIES; HUMAN BONE MORPHOGENETIC PROTEIN; INTERACTIVE EFFECT;

CONTROLLED DRUG DELIVERY;

ALKALINE PHOSPHATASE; CALCIUM SULFATE; CHITOSAN; MICROSPHERE; POLYETHYLENE; RECOMBINANT BONE MORPHOGENETIC PROTEIN 2; TISSUE SCAFFOLD; VANCOMYCIN;

ARTICLE; BACTERICIDAL ACTIVITY; BACTERIOSTASIS; BONE GRAFT; BONE REGENERATION; CELL VIABILITY; COMPOSITE GRAFT; CONTROLLED STUDY; DRUG DELIVERY SYSTEM; DRUG POTENCY; ELUTION; FREEZE DRYING; HARDNESS; IN VITRO STUDY; METHICILLIN RESISTANT STAPHYLOCOCCUS AUREUS; MICROTECHNOLOGY; MINIMUM INHIBITORY CONCENTRATION; NONHUMAN; PRIORITY JOURNAL; PROTEIN EXPRESSION; SUSTAINED DRUG RELEASE;

STAPHYLOCOCCUS AUREUS;

ABSORBABLE IMPLANTS; ANTI-BACTERIAL AGENTS; BONE MORPHOGENETIC PROTEIN 2; BONE SUBSTITUTES; CALCIUM SULFATE; CHITOSAN; DIFFUSION; DRUG COMBINATIONS; DRUG IMPLANTS; INTERCELLULAR SIGNALING PEPTIDES AND PROTEINS; MATERIALS TESTING; RECOMBINANT PROTEINS; TISSUE SCAFFOLDS; TRANSFORMING GROWTH FACTOR BETA; VANCOMYCIN;

EID: 84903696837     PISSN: 09574530     EISSN: 15734838     Source Type: Journal    
DOI: 10.1007/s10856-014-5167-7     Document Type: Article

References (52)

1. Bohner M. Resorbable biomaterials as bone graft substitutes. Mater Today. 2010;13:24-30.
2. Nair MB, Kretlow JD, Mikos AG, Kasper FK. Infection and tissue engineering in segmental bone defects mini review. Curr Opin Biotechnol. 2011;22:721-5.
3. Johnson EN, Burns TC, Hayda RA, Hospenthal DR, Murray CK. Infectious complications of open type III tibial fractures among combat casualties. Clin Infect Dis. 2007;15(45):409-15. (Pubitemid 47204454)
4. Owens BD, Kragh JF, Wenke JC, Macaitis J, Wade CE, Holcomb JB. Combat wounds in operation Iraqi Freedom and operation Enduring Freedom. J Trauma. 2008;64:295-9. (Pubitemid 351640430)
5. Owens BD, Kragh JF, Macaitis J, Svoboda SJ, Wenke JC. Characterization of extremity wounds in Operation Iraqi Freedom and Operation Enduring Freedom. J Orthop Trauma. 2007;21:254-7. (Pubitemid 46588274)
6. Wenke JC, Guelcher SA. Dual delivery of an antibiotic and a growth factor addresses both the microbiological and biological challenges of contaminated bone fractures. Expert Opin Drug Deliv. 2011;8:1555-69.
7. Bosse MJ, MacKenzie EJ, Kellam JF, Burgess AR, Webb LX, Swiontkowski MF, et al. An analysis of outcomes of reconstruction or amputation after leg-threatening injuries. N Engl J Med. 2002;12(347):1924-31. (Pubitemid 35429922)
8. Suzuki A, Terai H, Toyoda H, Namikawa T, Yokota Y, Tsunoda T, et al. A biodegradable delivery system for antibiotics and recombinant human bone morphogenetic protein-2: a potential treatment for infected bone defects. J Orthop Res. 2006;24:327-32. (Pubitemid 43772992)
9. Howell WR, Goulston C. Osteomyelitis: an update for hospitalists. Hosp Pract. 2011;39:153-60.
10. Jones RN. Resistance patterns among nosocomial pathogens: trends over the past few years. Chest. 2001;119:397S-404S. (Pubitemid 32163809)
11. Stewart RL, Cox JT, Volgas D, Stannard J, Duffy L, Waites KB, et al. The use of a biodegradable, load-bearing scaffold as a carrier for antibiotics in an infected open fracture model. J Orthop Trauma. 2010;24:587-91.
12. Thomas DB, Brooks DE, Bice TG, DeJong ES, Lonergan KT, Wenke JC. Tobramycin-impregnated calcium sulfate prevents infection in contaminated wounds. Clin Orthop Relat Res. 2005;441:366-71. (Pubitemid 44384246)
13. Noel SP, Courtney HS, Bumgardner JD, Haggard WO. Chitosan sponges to locally deliver amikacin and vancomycin: a pilot in vitro evaluation. Clin Orthop Relat Res. 2010;468:2074-80.
14. Nelson CL, Mclaren SG, Skinner RA, Smeltzer MS, Thomas JR, Olsen KM. The treatment of experimental osteomyelitis by surgical debridement and the implantation of calcium sulfate tobramycin pellets. East. 2002;20:643-7. (Pubitemid 34822981)
15. Rathbone CR, Cross JD, Brown KV, Murray CK, Wenke JC. Effect of various concentrations of antibiotics on osteogenic cell viability and activity. J Orthop Res. 2011;29:1070-4.
16. Gitelis S, Brebach GT. The treatment of chronic osteomyelitis with a biodegradable antibiotic-impregnated implant. J Orthop Surg. 2002;10:53-60. (Pubitemid 35332424)
17. Yarboro SR, Baum EJ, Dahners LE. Locally administered antibiotics for prophylaxis against surgical wound infection. An in vivo study. J Bone Joint Surg Am. 2007;89:929-33. (Pubitemid 46724580)
18. Hanssen AD. Local antibiotic delivery vehicles in the treatment of musculoskeletal infection. Clin Orthop Relat Res. 2005; 437:91-6. (Pubitemid 41099072)
19. Lee D-W, Yun Y-P, Park K, Kim SE. Gentamicin and bone morphogenic protein-2 (BMP-2)-delivering heparinized-titanium implant with enhanced antibacterial activity and osteointegration. Bone. 2012;50:974-82.
20. Liu S-J, Chi P-S, Lin S-S, Ueng SW-N, Chan E-C, Chen J-K. Novel solvent-free fabrication of biodegradable poly-lactic-glycolic acid (PLGA) capsules for antibiotics and rhBMP-2 delivery. Int J Pharm. 2007;7(330):45-53. (Pubitemid 46097358)
21. Li X, Xu J, Filion TM, Ayers DC, Song J. pHEMA-nHA encapsulation and delivery of vancomycin and rhBMP-2 enhances its role as a bone graft substitute. Clin Orthop Relat Res. 2013;471:2540-7.
22. Sinha VR, Singla AK, Wadhawan S, Kaushik R, Kumria R, Bansal K, et al. Chitosan microspheres as a potential carrier for drugs. Int J Pharm. 2004;15(274):1-33. (Pubitemid 38457003)
23. Glatt V, Kwong FN, Park K, Parry N, Griffin D, Vrahas M, et al. Ability of recombinant human bone morphogenetic protein 2 to enhance bone healing in the presence of tobramycin: evaluation in a rat segmental defect model. J Orthop Trauma. 2009;23: 693-701.
24. Strobel C, Bormann N, Kadow-Romacker A, Schmidmaier G, Wildemann B. Sequential release kinetics of two (gentamicin and BMP-2) or three (gentamicin, IGF-I and BMP-2) substances from a one-component polymeric coating on implants. J Control Release. 2011;30(156):37-45.
25. Wang Y, Wang X, Li H, Xue D, Shi Z, Qi Y, et al. Assessing the character of the rhBMP-2- and vancomycin-loaded calcium sulphate composites in vitro and in vivo. Arch Orthop Trauma Surg. 2011;131:991-1001.
26. Guelcher SA, Brown KV, Li B, Guda T, Lee B-H, Wenke JC. Dual-purpose bone grafts improve healing and reduce infection. J Orthop Trauma. 2011;25:477-82.
27. Lieberman JR, Daluiski A, Einhorn TA. The role of growth factors in the repair of bone. Biology and clinical applications. J Bone Joint Surg Am. 2002;84-A:1032-44.
28. Carragee EJ, Hurwitz EL, Weiner BK. A critical review of recombinant human bone morphogenetic protein-2 trials in spinal surgery: emerging safety concerns and lessons learned. Spine J. 2011;11:471-91.
29. Seeherman H, Wozney J, Li R. Bone morphogenetic protein delivery systems. Spine. 2002;27:S16-23.
30. Shi C, Zhu Y, Ran X, Wang M, Su Y, Cheng T. Therapeutic potential of chitosan and its derivatives in regenerative medicine. J Surg Res. 2006;15(133):185-92.
31. Khor E, Lim LY. Implantable applications of chitin and chitosan. Biomaterials. 2003;24:2339-49. (Pubitemid 36434054)
32. Chesnutt BM, Viano AM, Yuan Y, Yang Y, Guda T, Appleford MR, et al. Design and characterization of a novel chitosan/ nanocrystalline calcium phosphate composite scaffold for bone regeneration. J Biomed Mater Res. 2009;88:491-502.
33. Reves BT, Bumgardner JD, Cole JA, Yang Y, Haggard WO. Lyophilization to improve drug delivery for chitosan-calcium phosphate bone scaffold construct: a preliminary investigation. J Biomed Mater Res. 2009;90:1-10.
34. Bucholz RW. Nonallograft osteoconductive bone graft substitutes. Clin Orthop Relat Res. 2002;395:44-52. (Pubitemid 34136656)
35. Lewis G. Injectable bone cements for use in vertebroplasty and kyphoplasty: state-of-the-art review. J Biomed Mater Res. 2006; 76:456-68. (Pubitemid 43168280)
36. Thomas MV, Puleo DA. Calcium sulfate: properties and clinical applications. J Biomed Mater Res. 2009;88:597-610.
37. CLSI. Methods for dilution antimicrobial susceptibility tests for bacteria that grow aerobically; approved standard, CLSI document M07-A9. 9th ed. Wayne, PA: Clinical and Laboratory Standards Institute; 2012.
38. Winn SR, Hollinger JO. An osteogenic cell culture system to evaluate the cytocompatibility of Osteoset, a calcium sulfate bone void filler. Biomaterials. 2000;21:2413-25.
39. Wichelhaus TA, Dingeldein E, Rauschmann M, Kluge S, Dieterich R, Schäfer V, et al. Elution characteristics of vancomycin, teicoplanin, gentamicin and clindamycin from calcium sulphate beads. J Antimicrob Chemother. 2001;48:117-9. (Pubitemid 32684735)
40. Richelsoph KC, Webb ND, Haggard WO. Elution behavior of daptomycin-loaded calcium sulfate pellets: a preliminary study. Clin Orthop Relat Res. 2007;461:68-73.
41. Rauschmann MA, Wichelhaus TA, Stirnal V, Dingeldein E, Zichner L, Schnettler R, et al. Nanocrystalline hydroxyapatite and calcium sulphate as biodegradable composite carrier material for local delivery of antibiotics in bone infections. Biomaterials. 2005;26:2677-84. (Pubitemid 39600720)
42. Kwon B, Jenis LG. Carrier materials for spinal fusion. Spine J. 2005;5:224S-30S. (Pubitemid 41700065)
43. Li RH, Wozney JM. Delivering on the promise of bone morphogenetic proteins. Trends Biotechnol. 2001;19:255-65. (Pubitemid 32537763)
44. Calori GM, Donati D, Di Bella C, Tagliabue L. Bone morphogenetic proteins and tissue engineering: future directions. Injury. 2009;40(Suppl 3):S67-76.
45. Ricci JL, Alexander H, Nadkarni P, Hawkins M, Turner J, Rosenblum S, et al. Biological mechanisms of calcium sulfate replacement by bone. In: Davies JE, editor. Bone engineering. Toronto: Em2 Inc.; 2000. p. 332-44.
46. Coetzee AS. Regeneration of bone in the presence of calcium sulfate. Arch Otolaryngol. 1980;106:405-9. (Pubitemid 10071622)
47. Peltier LF. The use of plaster of paris to fill large defects in bone. Am J Surg. 1959;97:311-5.
48. Edin ML, Miclau T, Lester GE, Lindsey RW, Dahners LE. Effect of cefazolin and vancomycin on osteoblasts in vitro. Clin Orthop Relat Res. 1996;333:245-51. (Pubitemid 26428036)
49. Miclau T, Edin ML, Lester GE, Lindsey RW, Dahners LE. Bone toxicity of locally applied aminoglycosides. J Orthop Trauma. 1995;9:401-6.
50. Granjeiro JM, Oliveira RC, Bustos-Valenzuela JC, Sogayar MC, Taga R. Bone morphogenetic proteins: from structure to clinical use. Braz J Med Biol Res. 2005;38:1463-73. (Pubitemid 41440218)
51. Harwood PJ, Newman JB, Michael ALR. An update on fracture healing and non-union. Orthop Trauma. 2010;24:9-23.
52. AI-Aql ZS, Alagl AS, Graves DT, Gerstenfeld LC, Einhorn TA. Molecular mechanisms controlling bone formation during fracture healing and distraction osteogenesis. J Dent Res. 2008;87: 107-18.